Myeloproliferative neoplasms (MPN), including polycythemia vera (PV), essential thrombocythemia (ET),
and primary myelofibrosis (PMF), are clonal hematopoietic disorders characterized by excessive terminally
differentiated myeloid cells. MPNs can progress to secondary myelofibrosis or acute myeloid leukemia
(AML)/myelodysplastic syndromes (MDS). Although progress has been made in the understanding of the
pathogenesis and management of MPNs, there are still unresolved issues regarding prognosis, causes of
death, and risk factors for leukemic transformation. In patients with hematological malignancies, the risk of
suicide and suicide attempts is largely unknown.
We conducted a population-based study to establish patterns of survival in 9,384 MPN patients
identified from the Swedish Cancer Registry between 1973 and 2008. Relative survival ratios were computed
as measures of patient survival. Relative survival was significantly lower in all MPN subtypes compared to
expected survival in the general population, reflected in10-year relative survival ratios of 0.64 (95%
confidence interval (CI); 0.62-0.67) in PV, 0.68 (0.64-0.71) in ET, and 0.21 (0.18-0.25) in PMF,
respectively. Excess mortality was observed in patients of all MPN subtypes during all four calendar
periods (p <0.001). Nevertheless, survival improved significantly over time (p <0.001); however, the
improvement was less pronounced after the year 2000 and was confined to patients with PV and ET. In
conclusion, our findings underline the assertion that all MPNs should be considered serious diseases that
reduce life expectancy and highlight the need to improve treatment strategies for these patients.
Through the Swedish Cancer Registry and our national MPN cohort we identified 9,563 MPN patients
diagnosed between 1973 and 2005 and their 37,643 matched controls to assess excess mortality and causes
of death. Cumulative incidence functions, calculated using a flexible parametric model, were used to estimate
10-year probabilities of death with 95% CIs for six categories of causes of death. The 10-year probability of
dying from infections in male MPN patients aged 70-79 years at diagnosis were 4.5% (matched controls;
2.3%), from hematological malignancy 13.7% (0.2%), from cardiovascular disease 16.8% (15.0%), from
cerebrovascular disease 5.5% (5.1%), from solid tumor 9.7% (11.5%), and from other disorders 24.9%
(14.9%). The excess mortality in MPN patients declined due to a decrease in deaths from hematological
malignancies during the first calendar period (1973-1982), infections, and in younger MPN patients, from
cardiovascular disease. The overall improvement in 10-year mortality, observed in both patients and matched
controls over time, was mainly explained by declines in cardiovascular death. In conclusion, the improved
survival over time is multifactorial and can only partly be attributed to improved management of the
underlying hematological malignancy.
We conducted a nested case-control study to assess the role of MPN treatment and subsequent
AML/MDS risk. From a nationwide MPN cohort (n=11,039; diagnosed 1958-2005), we identified 162
patients (cases) with transformation (153 and nine with subsequent AML and MDS diagnosis, respectively)
and their 242 matched controls (MPN patients without AML/MDS transformation). Using logistic
regression, odds ratios (ORs) were calculated as measures of AML/MDS risk. Forty-one (25%) of the 162
MPN patients with AML/MDS transformation were never exposed to alkylating agents, radioactive
phosphorous (P32), or hydroxyurea (HU). The ORs for cases receiving 1 to 499 g, 500 to 999 g, more than
1,000 g of HU were 1.5 (95% CI; 0.6-2.4), 1.4 (0.6-3.4), and 1.3 (0.5-3.3), respectively, for AML/MDS
development (not significant). Patients with MPNs who received P32 doses greater than 1,000 MBq and
more than 1 g of alkylating agents had a 4.6-fold (2.1-9.8; p<0.002) and 3.4-fold (1.1-10.6; p<0.015)
increased risk of AML/MDS, respectively. Thus, the risk of AML/MDS development after MPN diagnosis
was not associated with HU treatment at any dosage. The fact that only 32% of patients with AML/MDS
transformation received doses found here to be leukemogenic indicates a major role for non-treatmentrelated factors.
To define incidence and risk factors for suicide and suicide attempts in patients with hematological
malignancies, we conducted a population-based study in 47,220 patients with hematological malignancies
and their 235,868 matched controls. Using Cox regression, the hazard ratios (HRs) for suicide and suicide
attempts (combined end-point) in patients with hematological malignancies was 1.9 (95% CI; 1.5-2.3)
compared to matched controls during the first three years after diagnosis. When more than three years had
elapsed, there was no excess risk of suicide/suicide attempts (HR 1.1; 0.9-1.4). Patients with multiple
myeloma carried the highest risk, HR 3.4 (2.3-5.0), and a pre-existing psychiatric disorder was strongly
associated with an increased risk of suicide and suicide attempts (HR 23.3; 16.6-32.6). Although suicides
contributed marginally to mortality in patients with hematological malignancies, awareness of risk factors for
suicide/suicide attempts can facilitate identification of high-risk patients and enable preventive intervention
